CULLINAN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.35 USD | +2.79% |
|
+12.06% | +178.21% |
| 04-29 | Cullinan Therapeutics Appoints Mary Kay Fenton as CFO | MT |
| 04-29 | Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer | CI |
| Sales 2024 * | 2.14M 171M | Sales 2025 * | 13.04M 1.04B | Capitalization | 1.22B 97.32B |
|---|---|---|---|---|---|
| Net income 2024 * | -175M -13.95B | Net income 2025 * | -189M -15.07B | EV / Sales 2024 * | 281 x |
| Net cash position 2024 * | 619M 49.35B | Net cash position 2025 * | 538M 42.92B | EV / Sales 2025 * | 52.3 x |
| P/E ratio 2024 * |
-8.35
x | P/E ratio 2025 * |
-8.94
x | Employees | 85 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.6% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cullinan Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +2.79% | ||
| 1 week | +12.06% | ||
| Current month | +4.96% | ||
| 1 month | +64.83% | ||
| 3 months | +59.72% | ||
| 6 months | +185.79% | ||
| Current year | +178.21% |
1 week
25.60
29.25
1 month
15.2029.25
Current year
10.0029.25
1 year
7.6429.25
3 years
7.3037.66
5 years
7.3059.85
10 years
7.3059.85
| Managers | Title | Age | Since |
|---|---|---|---|
Nadim Ahmed
CEO | Chief Executive Officer | 56 | 17/10/21 |
Jeffrey Jones
CTO | Chief Tech/Sci/R&D Officer | 53 | 27/02/22 |
Jacquelyn Sumer
CMP | Compliance Officer | 46 | 14/08/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 31/07/17 | |
Thomas Ebeling
BRD | Director/Board Member | 65 | 31/07/17 |
Stephen Webster
BRD | Director/Board Member | 63 | 31/08/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 28.35 | +2.79% | 975,213 |
| 02/05/24 | 27.58 | -1.85% | 986,391 |
| 01/05/24 | 28.1 | +4.04% | 1,442,282 |
| 30/04/24 | 27.01 | -0.41% | 1,420,120 |
| 29/04/24 | 27.12 | +7.19% | 2,703,008 |
Delayed Quote Nasdaq, May 03, 2024 at 09:15 pm
More quotes
Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
28.35
USD
Average target price
33.12
USD
Spread / Average Target
+16.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +178.21% | 1.22B | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- CGEM Stock
